CU20060115A7 - FORM OF TRANSDERMAL, LIQUID OR SEMISOLID ADMINISTRATION CONTAINING ACTIVE SUBSTANCE SENSITIVE TO LIGHT, STABLE TO ULTRAVIOLET RAYS - Google Patents

FORM OF TRANSDERMAL, LIQUID OR SEMISOLID ADMINISTRATION CONTAINING ACTIVE SUBSTANCE SENSITIVE TO LIGHT, STABLE TO ULTRAVIOLET RAYS

Info

Publication number
CU20060115A7
CU20060115A7 CU20060115A CU20060115A CU20060115A7 CU 20060115 A7 CU20060115 A7 CU 20060115A7 CU 20060115 A CU20060115 A CU 20060115A CU 20060115 A CU20060115 A CU 20060115A CU 20060115 A7 CU20060115 A7 CU 20060115A7
Authority
CU
Cuba
Prior art keywords
administration
light
transdermal
active substance
semisolid
Prior art date
Application number
CU20060115A
Other languages
Spanish (es)
Inventor
Stefan Bracht
Hans-Peter Podhaisky
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Priority to CU20060115A priority Critical patent/CU20060115A7/en
Publication of CU20060115A7 publication Critical patent/CU20060115A7/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

Formas de administración farmacéuticas semisólidas o líquidas para uso transdérmico que contiene una sustancia activa sensible a la luz UV y por lo menos una sustancia auxiliar (absorbedor de luz UV) que se encuentra presente en la forma de administración en forma disuelta o dispersa. Ventajosamente, la forma de administración de la invención se relaciona con geles transdérmicos, cuya base está formada por agua, alcohol, por lo menos un polímero formador de gel y si fuera necesario, otros componentes. Tales geles también se denominan geles hidroalcohólicos. Se pudo preparar una forma de administración que contiene una sustancia activa farmacéutica sensible a la luz, cuyo sistema de aplicación tiene elevada estabilidad y no presenta las desventajas conocidas que se presentan cuando se aplican formas de administración transdérmicas semisólidas convencionales. En esta forma de administración se minimizan los efectos secundarios daninos para el usuario que pueden resultar de la protección UV propuesta, como p. ej. la absorción de protector de luz por el cuerpo.Semisolid or liquid pharmaceutical administration forms for transdermal use containing an active substance sensitive to UV light and at least one auxiliary substance (UV light absorber) which is present in the form of administration in dissolved or dispersed form. Advantageously, the method of administration of the invention relates to transdermal gels, whose base is formed by water, alcohol, at least one gel-forming polymer and, if necessary, other components. Such gels are also called hydroalcoholic gels. An administration form containing a light sensitive pharmaceutical active substance could be prepared, the application system of which has high stability and does not have the known disadvantages that arise when conventional semi-solid transdermal administration forms are applied. In this form of administration, harmful side effects to the user that may result from the proposed UV protection, such as p. ex. The absorption of light protector by the body.

CU20060115A 2006-06-06 2006-06-06 FORM OF TRANSDERMAL, LIQUID OR SEMISOLID ADMINISTRATION CONTAINING ACTIVE SUBSTANCE SENSITIVE TO LIGHT, STABLE TO ULTRAVIOLET RAYS CU20060115A7 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CU20060115A CU20060115A7 (en) 2006-06-06 2006-06-06 FORM OF TRANSDERMAL, LIQUID OR SEMISOLID ADMINISTRATION CONTAINING ACTIVE SUBSTANCE SENSITIVE TO LIGHT, STABLE TO ULTRAVIOLET RAYS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060115A CU20060115A7 (en) 2006-06-06 2006-06-06 FORM OF TRANSDERMAL, LIQUID OR SEMISOLID ADMINISTRATION CONTAINING ACTIVE SUBSTANCE SENSITIVE TO LIGHT, STABLE TO ULTRAVIOLET RAYS

Publications (1)

Publication Number Publication Date
CU20060115A7 true CU20060115A7 (en) 2008-06-30

Family

ID=44280797

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20060115A CU20060115A7 (en) 2006-06-06 2006-06-06 FORM OF TRANSDERMAL, LIQUID OR SEMISOLID ADMINISTRATION CONTAINING ACTIVE SUBSTANCE SENSITIVE TO LIGHT, STABLE TO ULTRAVIOLET RAYS

Country Status (1)

Country Link
CU (1) CU20060115A7 (en)

Similar Documents

Publication Publication Date Title
UY28189A1 (en) TRANSDERMAL THERAPEUTIC SYSTEM STABLE TO UV RAYS.
GT200800075A (en) TRANSDERMAL THERAPEUTIC SYSTEM
UY28342A1 (en) NEW COMPOUNDS
CL2012002844A1 (en) Compounds derived from chromen-2-one; pharmaceutical composition that includes them; and its use in the treatment of a proliferative cell disorder such as cancer (divisional application No. 311-07).
AR051969A1 (en) METHODS AND COMPOSITIONS THAT USE IMMUNOMODULATING COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF INJURIES OF THE CENTRAL NERVOUS SYSTEM
UY28662A1 (en) ENDOPARASITICIDE AGENT FOR TOPICAL ADMINISTRATION
CR6656A (en) DOSAGE FORM OF DRUGS DRIVEN BY A HYDROGEL
UY26496A1 (en) PHARMACEUTICAL COMPOSITIONS PROVIDING POTENTIAL DRUG CONCENTRATIONS
CL2003002043A1 (en) COMPOUNDS DERIVED FROM TETRAHYDROPIRIDINE SUBSTITUTED IN POSITION 3 AND 4; PHARMACEUTICAL COMPOSITION, AND ITS USES IN THE TREATMENT OF DISEASES THAT ARE ASSOCIATED WITH THE RENINE-ANGIOTENSIN SYSTEM (RAS), SUCH AS HYPERTENSION, CARD INSUFFICIENCY
BRPI0518255A2 (en) Methods of treating or preventing a central nervous system injury to reduce or prevent an adverse effect, and pharmaceutical composition
UY31403A1 (en) "NOVEDOUS DERIVATIVES OF ({((3-Methylphenyl) -2H-TETRAZOL-5-IL) -ETOXI} -4H-1,2,4-TRIAZOL-3-IL), PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND MEDICAL USE OF THE SAME" .
CL2008001605A1 (en) An intranasal dosage formulation comprising asenapine or a pharmaceutically acceptable salt and a liquid carrier containing water and a polyol, useful for the treatment of schizophrenia.
CL2008003576A1 (en) 6,7-dihydro-5h-imidazo [1,2-alpha] imidazole-3-carboxylic acid amide derivative compounds; pharmaceutical composition comprising them; and uses in the treatment of an inflammatory condition.
CL2008002876A1 (en) Substituted heterocycle derived compounds, gamma-secretase modulators; pharmaceutical composition comprising them; use in the treatment of neurodegenerative diseases such as Alzheimer's or Down syndrome.
MXPA04002042A (en) SUBSTITUTED BENCIMIDAZOL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER.
CL2025002366A1 (en) Compound containing trifluoromethylsulfonyl.
AR075082A1 (en) USE OF VITAMIN E OR ITS DERIVATIVES FOR THE CONTROL OF ARTROPODES
BRPI0512183A (en) effective cosmetic or dermatological preparations for protection against
ECSP066689A (en) FORM OF TRANSDERMAL, LIQUID OR SEMISOLID ADMINISTRATION CONTAINING ACTIVE SUBSTANCE SENSITIVE TO LIGHT, STABLE TO ULTRAVIOLET RAYS
UY28667A1 (en) FORM OF TRANSDERMAL, LIQUID OR SEMISOLID ADMINISTRATION CONTAINING ACTIVE SUBSTANCE SENSITIVE TO LIGHT, STABLE TO ULTRAVIOLET RAYS.
GT200500349A (en) SUBSTITUTED BENZOXAZOL FORMULATIONS
ES2126409T3 (en) STABLE GELIFIED COMPOSITION CONTAINING LIPOPHILE ACTIVE AGENTS SENSITIVE TO OXYGEN AND / OR WATER.
BRPI0518554A2 (en) use of a pde3 inhibitor
EA200702344A1 (en) SOLID TRANSDERMAL THERAPEUTIC SYSTEM WITH UV ABSORBER
ES2177915T3 (en) USE OF MELATONIN FOR THE STABILIZATION OF COMPOSITIONS THAT INCLUDE HYDROPHYLE GELIFYING POLYMERS.